Tamtam Try Tamtam free
Walgreens Boots Alliance logo

Walgreens Boots Alliance account plan

Integrated healthcare and retail

At a glance

Walgreens Boots Alliance: US pharmacy, Boots and healthcare group, $147.7 billion of sales in fiscal 2024, private under Sycamore Partners since August 2025.

Walgreens Boots Alliance (WBA) is a pharmacy-led health and retail group whose brands include Walgreens, Duane Reade, Boots and Benavides. In fiscal 2024 (year ended August 31, 2024) it had sales of $147.7 billion, a net loss attributable to WBA of $8.6 billion and approximately 312,000 employees. On August 28, 2025 it was acquired by affiliates of Sycamore Partners, in partnership with Stefano Pessina and his family, who reinvested 100% of their interests, and its stock was delisted from Nasdaq. Following the closing, Walgreens, The Boots Group, Shields Health Solutions, CareCentrix and VillageMD operate as separate standalone companies, according to the closing press release; Walgreens is led by CEO Mike Motz.

Business units

Strategic priorities

Core pharmacy and retail focus
On closing, Walgreens CEO Mike Motz said the company is renewing its focus on its core pharmacy and retail platform, its stores and its customer experience. The fiscal 2024 10-K had already set a strategic review to build the core retail and specialty pharmacy business.
Store footprint optimization
The Footprint Optimization Program, approved on October 14, 2024, plans to close approximately 900 to 1,000 stores primarily across the U.S. by the end of fiscal 2027, or 1,200 to 1,300 stores including those left from the earlier program.
Stabilising pharmacy margins with PBMs
The U.S. Retail Pharmacy action plan includes collaborating and negotiating with PBMs to bring more stability to reimbursement, assessing provider status and new payment arrangements, and expanding owned brands in key categories.
Cost savings and cash discipline
The Transformational Cost Management Program reached annual savings of $4.5 billion at the end of fiscal 2024. Capital expenditure was cut by over $700 million in fiscal 2024 and net debt reduced by nearly $2.0 billion; the quarterly dividend was suspended on January 30, 2025.
Healthcare and in-store operations
Before the sale, CEO Tim Wentworth said investments would continue in multi-fulfillment sites to free up clinical time in stores, digital check-in and store resets, and that Sycamore expects WBA's team to lead the healthcare side.
Monetising VillageMD interests
Shareholders received one Divested Asset Proceed Right per share, worth up to $3.00 each from 70% of net proceeds of any monetisation of WBA's equity or debt interests in VillageMD.

Latest results

In the third quarter of fiscal 2025 (three months ended May 31, 2025), the last periodic report before the sale, sales were $38,986 million, up 7.2%, and operating income was $53 million versus $111 million a year earlier. Net loss attributable to WBA was $175 million and adjusted diluted EPS was $0.38 versus $0.63. U.S. Retail Pharmacy pharmacy sales rose 11.8% but retail sales fell 5.3%; U.S. Healthcare adjusted operating income was $54 million versus a loss of $22 million. Over nine months, 423 stores were closed. No guidance is given and WBA no longer reports publicly after the August 28, 2025 closing.

Investments and deals

Footprint Optimization Program
Estimated cumulative pre-tax charges of approximately $2.2 billion to $2.4 billion, with $473 million recognised since inception as of May 31, 2025.
Sycamore acquisition
Total cash payable to equityholders at closing was approximately $8.25 billion, at $11.45 per share, funded by Sycamore-affiliated funds, debt financing and reinvestment by Stefano Pessina.
Healthcare assets
VillageMD acquired Summit Health in fiscal 2023 (net of cash acquired $6.7 billion). VillageMD took a $12.4 billion goodwill impairment in fiscal 2024 and WBA signed a forbearance agreement on its $2.25 billion secured loan on August 6, 2024.
Financing and asset sales
A $2.5 billion accounts receivable facility was set up on April 24, 2025, and approximately $2.7 billion of Cencora shares were sold in fiscal 2024.

Challenges and risks

Reimbursement pressure and payor concentration
Three third-party payors were approximately 34% of consolidated sales in fiscal 2024, and WBA reports continuing reimbursement pressure from PBMs and government plans.
Weak retail sales
U.S. Retail Pharmacy retail sales fell 4.6% in fiscal 2024 and 5.3% in the quarter to May 31, 2025, weaker in grocery and household, health and wellness, and beauty.
Impairments and losses
Fiscal 2024 included a $12.7 billion goodwill impairment and a net loss attributable to WBA of $8.6 billion; the nine months to May 31, 2025 added $4.3 billion of impairment charges attributable to WBA.
Opioid liabilities
WBA accrued a $6.6 billion liability for opioid-related claims, with payments over the next 15 years.
Single wholesaler dependence
The 10-K lists reliance on one wholesaler, Cencora, as primary source of branded and generic drugs as a risk.

What leadership says

“we are renewing our focus on our core pharmacy and retail platform, our stores and our customer experience”

Mike Motz, Chief Executive Officer, Walgreens · Walgreen Co. press release on the closing of the Sycamore acquisition, August 28, 2025

“move with certainty, speed and focus”

Stefan Kaluzny, Managing Director, Sycamore Partners · Walgreen Co. press release, August 28, 2025

“arguably we're in the first third of a turnaround”

Tim Wentworth, former Chief Executive Officer, Walgreens Boots Alliance · U.S. Town Hall, March 7, 2025

“every dollar we spend is spent toward growing the business or running it effectively”

Tim Wentworth, former Chief Executive Officer, Walgreens Boots Alliance · Employee town hall, May 8, 2025

Where a supplier can help

Store closure and real estate execution
Tied to the Footprint Optimization Program (900 to 1,000 stores by the end of fiscal 2027): lease exit, asset disposal, prescription transfer and workforce transition services.
Pharmacy reimbursement and PBM analytics
Tied to the margin pressure and payor concentration: tools for contract modelling, claims reconciliation and network performance across PBMs.
Retail turnaround and assortment tools
Tied to the focus on stores and customer experience and the fall in retail sales: assortment, pricing and promotion, shrink reduction and store-level analytics.
Standalone company set-up
Tied to Walgreens, Boots, Shields, CareCentrix and VillageMD running as separate companies: separation of IT, finance, procurement and shared services.
Healthcare services and fulfillment
Tied to the priority on freeing clinical time (multi-fulfillment sites, digital check-in) and the Walgreens Health, Shields and CareCentrix businesses: automation, patient engagement and care coordination software.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Walgreens Boots Alliance?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Walgreens Boots Alliance

Who owns Walgreens Boots Alliance?

Affiliates of Sycamore Partners acquired it on August 28, 2025, in partnership with Stefano Pessina and his family, who reinvested 100% of their interests. Its stock no longer trades on Nasdaq.

How big is Walgreens Boots Alliance?

In fiscal 2024 it had sales of $147.7 billion and approximately 312,000 employees. At the closing, Walgreens described approximately 8,500 stores in the U.S. and Puerto Rico and approximately 220,000 team members.

How is the group organised now?

The closing press release says Walgreens, The Boots Group, Shields Health Solutions, CareCentrix and VillageMD operate as separate standalone companies. Before the sale WBA reported three segments: U.S. Retail Pharmacy, International and U.S. Healthcare.

Who leads Walgreens?

Mike Motz became CEO of Walgreens on August 28, 2025, replacing Tim Wentworth, who stays as a Director. John Lederer is Executive Chairman of Walgreens.

What is Walgreens' strategy?

Renewed focus on the core pharmacy and retail platform, stores and customer experience, together with a program to close approximately 900 to 1,000 stores primarily across the U.S. by the end of fiscal 2027.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-19)